FXN

Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders

Retrieved on: 
Thursday, July 28, 2022
Gene expression, GLOBE, FXN, Discovery, Bioinformatics discovery of non-coding RNAs, Therapy, Conference, Expression, Friedreich's ataxia, Neuroscience, Neurodegeneration, Nasdaq, Poster, LRMR, Vaccine

BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that preclinical studies evaluating CTI-1601s effects on gene expression and neurodegeneration will be featured in a poster at the upcoming Gordon Research Conference on Neurobiology of Brain Disorders .

Key Points: 
  • BALA CYNWYD, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that preclinical studies evaluating CTI-1601s effects on gene expression and neurodegeneration will be featured in a poster at the upcoming Gordon Research Conference on Neurobiology of Brain Disorders .
  • The conference will take place August 7 12, 2022 at the Rey Don Jaime Grand Hotel in Castelldefels, Spain.
  • The posters presenting author is David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics.
  • Larimar Therapeutics, Inc.(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.

Gerresheimer on track to deliver record financial year 2022 after solid second quarter

Retrieved on: 
Wednesday, July 13, 2022
AG, EPS, EBITDA, Solution, Foundation, GM High Value engine, Beauty, Environment, Syringe, Plastic, Glass, Pharma, CEO, FY, Parkinson's disease, FXN, EUR, Cosmetics, Growth, Administration, GAT, Contract, Fine chemical

EPS in FY2022

Key Points: 
  • EPS in FY2022
    DUSSELDORF, Germany, July 13, 2022 /PRNewswire/ --Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirms its guidance for its financial year 2022 after delivering a solid second quarter in line with plan.
  • Gerresheimer reaffirms its guidance for its financial year 2022 with double-digit organic revenue growth and high single-digit organic growth in adjusted EBITDA and adjusted EPS.
  • In the second quarter of its 2022 financial year, Gerresheimer generated revenues of EUR 445m, representing an organic growth of 13%.
  • In the second quarter, Gerresheimer entered into strategic participations with Portal Instruments Inc to develop a needle-free autoinjector and with Adamant Health Oy to revolutionize the treatment of Parkinson's disease.

Gerresheimer on track to deliver record financial year 2022 after solid second quarter

Retrieved on: 
Wednesday, July 13, 2022
AG, EPS, EBITDA, Solution, Foundation, GM High Value engine, Beauty, Environment, Syringe, Plastic, Glass, Pharma, CEO, FY, Parkinson's disease, FXN, EUR, Cosmetics, Growth, Administration, GAT, Contract, Fine chemical

EPS in FY2022

Key Points: 
  • EPS in FY2022
    DUSSELDORF, Germany, July 13, 2022 /PRNewswire/ --Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirms its guidance for its financial year 2022 after delivering a solid second quarter in line with plan.
  • Gerresheimer reaffirms its guidance for its financial year 2022 with double-digit organic revenue growth and high single-digit organic growth in adjusted EBITDA and adjusted EPS.
  • In the second quarter of its 2022 financial year, Gerresheimer generated revenues of EUR 445m, representing an organic growth of 13%.
  • In the second quarter, Gerresheimer entered into strategic participations with Portal Instruments Inc to develop a needle-free autoinjector and with Adamant Health Oy to revolutionize the treatment of Parkinson's disease.

DGAP-News: Gerresheimer AG: Gerresheimer on track to deliver record financial year 2022 after solid second quarter

Retrieved on: 
Wednesday, July 13, 2022
EPS, EBITDA, Solution, Foundation, GM High Value engine, Beauty, Environment, Syringe, Plastic, Glass, Pharma, CEO, FXN, EUR, Cosmetics, Growth, Administration, GAT, Contract, Fine chemical, Medical device

Firmly on track to deliver double digit revenue growth with high single-digit growth in adj.

Key Points: 
  • Firmly on track to deliver double digit revenue growth with high single-digit growth in adj.
  • EPS in FY2022
    Duesseldorf, July 13, 2022 Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug delivery systems for pharma, biotech and cosmetics, reaffirms its guidance for its financial year 2022 after delivering a solid second quarter in line with plan.
  • Gerresheimer reaffirms its guidance for its financial year 2022 with double-digit organic revenue growth and high single-digit organic growth in adjusted EBITDA and adjusted EPS.
  • In the second quarter of its 2022 financial year, Gerresheimer generated revenues of EUR 445m, representing an organic growth of 13%.

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs Development Report 2022: 21 Molecules with Approximately 15 Molecules Developed by Companies, Remaining by Universities - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, Pharmaceutical, Health, Molecule, Discovery, R, Therapy, Heme, Cerebellar ataxia, Mall of America, FXN, Protein, Cardiomyopathy, SEC, Central nervous system, EC, Fine chemical

The "Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • Frataxin Mitochondrial - Drugs In Development 2022 outlays comprehensive information on the Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Frataxin is a protein encoded by the FXN gene.
  • Furthermore, this report also reviews key players involved in Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Nu Holdings Ltd. Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022
Professional Services, Technology, Mobile, Wireless, Software, Finance, Internet, Banking, Company, Population, SME, FX, International, NU, U.S. Securities and Exchange Commission, Webcast, Financial result, Financial condition report, Result, Mission statement, Analysis, Investor relations, FXN, Adult, Securities Act of 1933, Industry, Conference, Asset quality, Holding, International expansion of Netflix, Technology, IFRS, NPL, Yoy, International Financial Reporting Standards, Security (finance), Acquisition, Growth, Prospectus, NYSE, Annual report, CEO, Video game, Bank, Drug, Real estate, Online shopping, Risk management, Audit

Nu Holdings Ltd. (NYSE: NU | B3: NUBR33), (Nu or the Company), one of the worlds largest digital banking platforms, released today its First Quarter 2022 financial results.

Key Points: 
  • Nu Holdings Ltd. (NYSE: NU | B3: NUBR33), (Nu or the Company), one of the worlds largest digital banking platforms, released today its First Quarter 2022 financial results.
  • Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards (IFRS).
  • Below are Q122 performance highlights of Nu Holdings Ltd.:
    Customer growth: Nu added 5.7 million customers in the quarter, reaching a total of 59.6 million customers in Brazil, Mexico and Colombia.
  • Nu estimates that over 54% of the total active customers that have been with Nu for more than 12 months have chosen Nu as their primary banking relationship.

LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Tuesday, May 3, 2022
Drug development, School, APOE4, Cardiomyopathy, University, Peripheral nervous system, Mortality, Mouse, Echocardiography, NEW, CNS, GLOBE, Real-time, PKP2, Cell, AAV, Fibrosis, Gene, Survival, University of California, San Diego, Degenerative disease, FA, Medicine, 2021 Essex County Council election, Primate, Adult, FXN, LinkedIn, Society, Batten disease, Technology, Research, Heart, Zygosity, Central nervous system, Weill Cornell Medicine, ARVC, Therapy, Vaccine, Pharmaceutical industry

This year we are presenting important preclinical data supporting our most advanced cardiovascular gene therapy programs in FA and ARVC, said Nolan Townsend, Chief Executive Officer of LEXEO.

Key Points: 
  • This year we are presenting important preclinical data supporting our most advanced cardiovascular gene therapy programs in FA and ARVC, said Nolan Townsend, Chief Executive Officer of LEXEO.
  • The advances in these programs and others will help bolster our leadership position in the cardiovascular gene therapy category.
  • Four abstracts, including two oral presentations, were selected for ASGCT.
  • Study researchers hypothesized that PKP2 protein dose is a critical driver of ARVC, and that PKP2 gene therapy via AAV strategies can prevent and rescue ARVC development.

DGAP-News: Gerresheimer AG: Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

Retrieved on: 
Tuesday, April 12, 2022
EBITDA, Degenerative disease, Plastic, Pharma, Environment, CEO, FX, Cosmetics, Administration, Contract, Solution, Beauty, FXN, EUR, Video game, Fine chemical, Gerresheimer

The company delivered double-digit growth in both revenue and adjusted EBITDA in the first quarter and raises its 2022 revenue guidance.

Key Points: 
  • The company delivered double-digit growth in both revenue and adjusted EBITDA in the first quarter and raises its 2022 revenue guidance.
  • "We delivered an excellent first quarter demonstrating that our growth investments are paying off", said Dietmar Siemssen, CEO of Gerresheimer AG.
  • The development gives us the confidence to raise our revenue guidance for 2022 to double-digit organic revenue growth."
  • Based on the successful development in the first quarter and the strong order book, Gerresheimer has raised its guidance for organic revenue growth in 2022.

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Retrieved on: 
Wednesday, March 30, 2022
ClinicalTrials.gov, Friedreich's Ataxia Research Alliance, White Light Rock & Roll Review, Private Securities Litigation Reform Act, Therapy, Cell, Drug development, Risk, Heart, Fast Track, SAD, Gene expression, Degenerative disease, Clinical trial, Pharmacokinetics, Friedreich's ataxia, Adult, CNS, Research, GAA, SEC, Program, Food, U.S. Securities and Exchange Commission, Communication, Accelerated approval (FDA), FARA, Security (finance), Lists of diseases, Industry, Safety, Review, MS, Priority review, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mutation, GLOBE, NDA, FXN, Nature, FDA, Patient, Disease, Pharmaceutical industry, Medical device, Design, FA, Nikolaus Friedreich

CARLSBAD, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for degenerative genetic disorders, today announced that it has completed dosing in the first single ascending dose (SAD) cohort of its Phase 1 clinical trial of DT-216 in patients with Friedreich ataxia (FA). DT-216 is a novel GeneTAC™ gene targeted chimera small molecule designed to specifically target the GAA repeat expansion mutation, the underlying cause of FA, and restore frataxin (FXN) gene expression. Additionally, Design announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DT-216 for the treatment of patients with FA.

Key Points: 
  • Additionally, Design announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DT-216 for the treatment of patients with FA.
  • The FDAs decision to grant Fast Track designation to DT-216 reflects the tremendous need for an effective treatment for people with FA.
  • Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC gene targeted chimera small molecules.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, March 10, 2022
Molecule, Heart, Nasdaq, Safety, Industry, Clinical trial, D, Patient, Drug development, Risk, FXN, Private Securities Litigation Reform Act, IND, Research, U.S. Securities and Exchange Commission, Cerebellar ataxia, Degenerative disease, Therapy, FDA, Pharmacokinetics, Friedreich's ataxia, Ophthalmology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Severe cognitive impairment, ARVO, FA, Appointment, CNS, Nature, Myotonic dystrophy, GLOBE, Gene expression, Treatment, Security (finance), G&A, Disease, FACC, SEC, Food, Association, Design, Biotechnology, Program, R, Pharmaceutical industry, Fuchs

CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results.

Key Points: 
  • 2022 is set to be a meaningful year for Design, with key upcoming milestones and a pipeline comprised of potentially transformative new genomic medicines.
  • R&D Expenses: Research and development (R&D) expenses were$7.3millionfor the quarter ended December 31, 2021, and $24.8 million for the year ended December 31, 2021.
  • G&A Expenses: General and administrative (G&A) expenses were$3.8millionfor the quarter ended December 31, 2021, and $11.1 million for the year ended December 31, 2021.
  • Net Loss: Net loss was$11.1 million for the quarter ended December 31, 2021, and $35.5 million for the year ended December 31, 2021.